Treatment of neuromyelitis optica

Review and recommendations

Dorlan J. Kimbrough, Kazuo Fujihara, Anu Jacob, Marco A. Lana-Peixoto, Maria Isabel Leite, Michael Levy, Romain Marignier, Ichiro Nakashima, Jacqueline Palace, Jrme De Seze, Olaf Stuve, Silvia N. Tenembaum, Anthony Traboulsee, Emmanuelle Waubant, Brian G. Weinshenker, Dean M. Wingerchuk

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices.

Original languageEnglish (US)
Pages (from-to)180-187
Number of pages8
JournalMultiple Sclerosis and Related Disorders
Volume1
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Neuromyelitis Optica
Multiple Sclerosis
Mycophenolic Acid
Mitoxantrone
Azathioprine
Immunologic Factors
Demyelinating Diseases
Immunosuppressive Agents
Optic Nerve
Prednisone
Methotrexate
Interferons
Autoimmune Diseases
Spinal Cord
Prospective Studies
Pathology

Keywords

  • Aquaporin 4
  • Immunosuppression
  • Neuromyelitis optica
  • NMO treatment
  • Optic neuritis
  • Transverse myelitis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Kimbrough, D. J., Fujihara, K., Jacob, A., Lana-Peixoto, M. A., Isabel Leite, M., Levy, M., ... Wingerchuk, D. M. (2012). Treatment of neuromyelitis optica: Review and recommendations. Multiple Sclerosis and Related Disorders, 1(4), 180-187. https://doi.org/10.1016/j.msard.2012.06.002

Treatment of neuromyelitis optica : Review and recommendations. / Kimbrough, Dorlan J.; Fujihara, Kazuo; Jacob, Anu; Lana-Peixoto, Marco A.; Isabel Leite, Maria; Levy, Michael; Marignier, Romain; Nakashima, Ichiro; Palace, Jacqueline; De Seze, Jrme; Stuve, Olaf; Tenembaum, Silvia N.; Traboulsee, Anthony; Waubant, Emmanuelle; Weinshenker, Brian G.; Wingerchuk, Dean M.

In: Multiple Sclerosis and Related Disorders, Vol. 1, No. 4, 10.2012, p. 180-187.

Research output: Contribution to journalArticle

Kimbrough, DJ, Fujihara, K, Jacob, A, Lana-Peixoto, MA, Isabel Leite, M, Levy, M, Marignier, R, Nakashima, I, Palace, J, De Seze, J, Stuve, O, Tenembaum, SN, Traboulsee, A, Waubant, E, Weinshenker, BG & Wingerchuk, DM 2012, 'Treatment of neuromyelitis optica: Review and recommendations', Multiple Sclerosis and Related Disorders, vol. 1, no. 4, pp. 180-187. https://doi.org/10.1016/j.msard.2012.06.002
Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Isabel Leite M, Levy M et al. Treatment of neuromyelitis optica: Review and recommendations. Multiple Sclerosis and Related Disorders. 2012 Oct;1(4):180-187. https://doi.org/10.1016/j.msard.2012.06.002
Kimbrough, Dorlan J. ; Fujihara, Kazuo ; Jacob, Anu ; Lana-Peixoto, Marco A. ; Isabel Leite, Maria ; Levy, Michael ; Marignier, Romain ; Nakashima, Ichiro ; Palace, Jacqueline ; De Seze, Jrme ; Stuve, Olaf ; Tenembaum, Silvia N. ; Traboulsee, Anthony ; Waubant, Emmanuelle ; Weinshenker, Brian G. ; Wingerchuk, Dean M. / Treatment of neuromyelitis optica : Review and recommendations. In: Multiple Sclerosis and Related Disorders. 2012 ; Vol. 1, No. 4. pp. 180-187.
@article{b58ca9c530354e88a0d06034728cb4b9,
title = "Treatment of neuromyelitis optica: Review and recommendations",
abstract = "Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices.",
keywords = "Aquaporin 4, Immunosuppression, Neuromyelitis optica, NMO treatment, Optic neuritis, Transverse myelitis",
author = "Kimbrough, {Dorlan J.} and Kazuo Fujihara and Anu Jacob and Lana-Peixoto, {Marco A.} and {Isabel Leite}, Maria and Michael Levy and Romain Marignier and Ichiro Nakashima and Jacqueline Palace and {De Seze}, Jrme and Olaf Stuve and Tenembaum, {Silvia N.} and Anthony Traboulsee and Emmanuelle Waubant and Weinshenker, {Brian G.} and Wingerchuk, {Dean M.}",
year = "2012",
month = "10",
doi = "10.1016/j.msard.2012.06.002",
language = "English (US)",
volume = "1",
pages = "180--187",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Treatment of neuromyelitis optica

T2 - Review and recommendations

AU - Kimbrough, Dorlan J.

AU - Fujihara, Kazuo

AU - Jacob, Anu

AU - Lana-Peixoto, Marco A.

AU - Isabel Leite, Maria

AU - Levy, Michael

AU - Marignier, Romain

AU - Nakashima, Ichiro

AU - Palace, Jacqueline

AU - De Seze, Jrme

AU - Stuve, Olaf

AU - Tenembaum, Silvia N.

AU - Traboulsee, Anthony

AU - Waubant, Emmanuelle

AU - Weinshenker, Brian G.

AU - Wingerchuk, Dean M.

PY - 2012/10

Y1 - 2012/10

N2 - Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices.

AB - Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices.

KW - Aquaporin 4

KW - Immunosuppression

KW - Neuromyelitis optica

KW - NMO treatment

KW - Optic neuritis

KW - Transverse myelitis

UR - http://www.scopus.com/inward/record.url?scp=84865262140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865262140&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2012.06.002

DO - 10.1016/j.msard.2012.06.002

M3 - Article

VL - 1

SP - 180

EP - 187

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

IS - 4

ER -